Pittsburgh, PANCT07439887Now EnrollingIRB Ready

Stargardt Disease Clinical Trial in Pittsburgh, PA

Access cutting-edge stargardt disease treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Ray Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access stargardt disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stargardt disease treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this stargardt disease clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Stargardt Disease Study in Pittsburgh

A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in up to 3 dose cohorts of RTx-021. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-021 in the study eye and be followed for 5 years.

Sponsor: Ray Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Male and female patients \>= 16 years of age
Able to comply with the study visit schedule and all protocol assessments
Diagnosis of Stargardt Disease (genetic testing required)
Study eye and fellow eye Best Corrected Visual Acuity meeting study criteria
Presence of retinal ganglion cells and/or retinal nerve fiber layer on Spectral Domain Optical Coherence Tomography testing at Screening confirmed by central image reading center
Adequate organ function and general good health

Exclusion Criteria

Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent, or therapy in the past six months
Concurrent participation in another interventional clinical ocular study
Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy
Pre-existing eye conditions in either eye that would preclude the planned treatment or are significant enough to interfere with the interpretation of study endpoints or procedural complications
Known steroid responders if their intraocular pressure was not able to be managed effectively with topical pressure-lowering medications after prior use of steroid medications
Complicating systemic diseases including those in which the disease itself, or the treatment of the disease, can alter ocular and/or central nervous system function (e.g. radiation treatment of the orbit; leukemia with optic nerve involvement)
Any immunological response dysfunction including, immuno-compromising diseases or use of immunosuppressive medications, among others
Cataract or other ocular (including refractive) surgery, intraocular and/or peri-ocular injection in either eye within the prior four months (i.e. 120 days) prior to screening
Prior vitrectomy or aphakia in the study eye
Known sensitivity to any component of the study treatment or contraindication to medications planned for use in the peri-procedural period (e.g. povidone-iodine to prep for intravitreal injection)
Known contraindication to prophylactic steroid regimen
Current pregnancy or breastfeeding
Any other condition that would not allow the patient to complete follow-up examinations during the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT07439887) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stargardt Disease Treatment Options in Pittsburgh, PA

If you're searching for stargardt disease treatment options in Pittsburgh, PA, this clinical trial (NCT07439887) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stargardt disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stargardt disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Pittsburgh, PA

See all ankylosing spondylitis clinical trials recruiting in Pittsburgh — not just this study.

Browse Ankylosing Spondylitis Trials in Pittsburgh →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA